Virtus ETF Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$110K Buy
120
+100
+500% +$101K 0.05% 325
2025
Q4
$21.5K Sell
20
-80
-80% -$76.5K 0.01% 439
2025
Q3
$76.3K Sell
100
-129
-56% -$96K 0.04% 345
2025
Q2
$179K Buy
+229
New +$178K 0.11% 221
2025
Q1
Sell
-1,287
Closed -$994K 630
2024
Q4
$994K Buy
1,287
+187
+17% +$155K 0.41% 127
2024
Q3
$975K Buy
+1,100
New +$989K 0.46% 52
2024
Q2
Sell
-1,204
Closed -$937K 467
2024
Q1
$937K Buy
1,204
+192
+19% +$137K 0.5% 25
2023
Q4
$590K Buy
+1,012
New +$591K 0.37% 111
2023
Q3
Sell
-2,061
Closed -$967K 461
2023
Q2
$967K Sell
2,061
-532
-21% -$223K 0.57% 17
2023
Q1
$890K Buy
2,593
+328
+14% +$111K 0.49% 59
2022
Q4
$829K Buy
2,265
+187
+9% +$66.3K 0.43% 57
2022
Q3
$672K Sell
2,078
-523
-20% -$166K 0.27% 122
2022
Q2
$843K Buy
+2,601
New +$781K 0.31% 92
2018
Q3
Sell
-328
Closed -$28K 356
2018
Q2
$28K Buy
328
+35
+12% +$2.88K 0.02% 174
2018
Q1
$23K Hold
293
0.02% 170
2017
Q4
$25K Buy
+293
New +$24.9K 0.03% 167

Other funds holding LLY

Virtus ETF Advisers's LLY Position: Q1 2026 in Review

Virtus ETF Advisers increased its Eli Lilly (LLY) stake by 500% in Q1 2026, buying an estimated $101K and bringing the position to 120 shares worth $110K. The position accounts for 0.05% of the portfolio, ranked #325.

Virtus ETF Advisers first reported a position in LLY in Q4 2017 and has held it in 16 quarters since. The position peaked at $994K in Q4 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Virtus ETF Advisers held 120 shares of Eli Lilly worth $110K as of Q1 2026.
  • Virtus ETF Advisers bought 100 Eli Lilly shares in Q1 2026, an estimated $101K.
  • Eli Lilly made up 0.05% of Virtus ETF Advisers's portfolio in Q1 2026, its #325 holding.
  • Virtus ETF Advisers first reported a position in Eli Lilly in Q4 2017 and has held it in 16 quarters since.
  • Virtus ETF Advisers's Eli Lilly position peaked at $994K in Q4 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.